Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 4/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | ITK | Q08881 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178411 | 1.00 | GPR84 (0.45) | GPR84AXLCDK8MAPK1PIK3CD | |
| SCHEMBL18012904 | 0.80 | GPR84 (0.45) | GPR84AXLCDK8PIK3CDPIK3CA | |
| SCHEMBL5925932 | 0.79 | GPR84 (0.48) | GPR84AXLCDK8MAPK1PIK3CD | |
| SCHEMBL1565089 | 0.76 | AXL (0.41) | GPR84AXLCDK8MAPK1PIK3CD | |
| SCHEMBL16621143 | 0.76 | GPR84 (0.45) | GPR84AXLCDK8MAPK1PIK3CD | |
| SCHEMBL9288889 | 0.76 | GPR84 (0.45) | GPR84AXLCDK8MAPK1PIK3CD | |
| SCHEMBL31398506 | 0.76 | CSNK2A1 (0.44) | AXLCDK8MAPK1PIK3CDPIK3CA | |
| SCHEMBL23094481 | 0.72 | CDK8 (0.40) | AXLCDK8MAPK1PIK3CDPIK3CA | |
| SCHEMBL31438054 | 0.72 | RIPK1 (0.43) | GPR84AXLCDK8PIK3CDPIK3CA | |
| SCHEMBL17998758 | 0.72 | GPR84 (0.41) | GPR84AXLCDK8PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410190-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250179090-A1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2025-06-05 | — | — | US | disclosed |
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-08-31 | — | — | US | disclosed |
| EP-4227311-A1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-3672975-B1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| CN-111448198-B | Condensed heterocyclic derivatives as Bcl-2 inhibitors for the treatment of neonatal diseases | 广州麓鹏制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220220126-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | BCL2, BCL3, BCL2A1 | GPR84 3715/4885AXL 4449/4885CDK8 249/4885 |
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL3, BCL2L10 | GPR84 3604/4885AXL 4707/4885CDK8 188/4885 |
| US-20250179090-A1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL2L11, BCL2L10 | GPR84 3789/4885AXL 4745/4885CDK8 193/4885 |
| US-12410190-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | BCL2, BCL3, BCL2L10 | GPR84 3604/4885AXL 4707/4885CDK8 188/4885 |
| US-20220220126-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL3, BCL2L10 | GPR84 3604/4885AXL 4707/4885CDK8 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.